RCT: Pain and health-related quality of life with olaparib vs. physician’s choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations.

Pain and health-related quality of life with olaparib versus physician’s choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Pain and Quality of Life in the PROfound Trial: Olaparib vs Next-Generation Hormonal Agent in Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations – The ASCO Post